News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioForm Inc. to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007


12/5/2007 11:55:37 AM

SAN MATEO, Calif., Dec. 5 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. announced that on Thursday, December 13, 2007, it will report its September 30, 2007 first quarter fiscal year 2008 financial results. The Company will issue the earnings press release after the NASDAQ Global Market closes and will hold a conference call with investors at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).

BioForm Chief Executive Officer Steve Basta and Chief Financial Officer Derek Bertocci will discuss the Company's results for the first quarter fiscal year 2008 and its future outlook for the fiscal year 2008. The conference call will be webcast live on the Investor Relations section of BioForm's website at www.bioform.com. The online archive of the broadcast will be available approximately 90 minutes after the live call and will continue to be available for two weeks.

The conference call may be accessed by dialing 888.661.5138 for callers in the U.S. and 913.312.0952 for international callers. Please notify the operator that you would like to join "BioForm Medical's First Quarter Earnings Call" and provide the participant code "2949717", if prompted.

About BioForm Medical, Inc.: BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm's products include Radiesse(R), a long-lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm has licensed U.S. marketing rights to Aethoxysklerol(R), the worldwide leading sclerotherapy agent, which is currently being evaluated in a Phase III clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc.

CONTACT: Adam Gridley, Vice President, Corporate Development, BioForm
Medical, Inc., +1-650-286-4025

Web site: http://www.bioformmedical.com//


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES